Cargando…
Anticancer Activities of Mushrooms: A Neglected Source for Drug Discovery
Approximately 270 species of mushrooms have been reported as potentially useful for human health. However, few mushrooms have been studied for bioactive compounds that can be helpful in treating various diseases. Like other natural regimens, the mushroom treatment appears safe, as could be expected...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876642/ https://www.ncbi.nlm.nih.gov/pubmed/35215289 http://dx.doi.org/10.3390/ph15020176 |
_version_ | 1784658221897613312 |
---|---|
author | Panda, Sujogya Kumar Sahoo, Gunanidhi Swain, Shasank S. Luyten, Walter |
author_facet | Panda, Sujogya Kumar Sahoo, Gunanidhi Swain, Shasank S. Luyten, Walter |
author_sort | Panda, Sujogya Kumar |
collection | PubMed |
description | Approximately 270 species of mushrooms have been reported as potentially useful for human health. However, few mushrooms have been studied for bioactive compounds that can be helpful in treating various diseases. Like other natural regimens, the mushroom treatment appears safe, as could be expected from their long culinary and medicinal use. This review aims to provide a critical discussion on clinical trial evidence for mushrooms to treat patients with diverse types of cancer. In addition, the review also highlights the identified bioactive compounds and corresponding mechanisms of action among the explored mushrooms. Furthermore, it also discusses mushrooms with anticancer properties, demonstrated either in vitro and/or in vivo models, which have never been tested in clinical studies. Several mushrooms have been tested in phase I or II clinical trials, mostly for treating breast cancer (18.6%), followed by colorectal (14%) and prostate cancer (11.6%). The majority of clinical studies were carried out with just 3 species: Lentinula edodes (22.2%), Coriolus versicolor, and Ganoderma lucidum (both 13.9%); followed by two other species: Agaricus bisporus and Grifola frondosa (both 11.1%). Most in vitro cell studies use breast cancer cell lines (43.9%), followed by lung (14%) and colorectal cancer cell lines (13.1%), while most in vivo animal studies are performed in mice tumor models (58.7%). Although 32 species of mushrooms at least show some promise for the treatment of cancer, only 11 species have been tested clinically thus far. Moreover, most clinical studies have investigated fewer numbers of patients, and have been limited to phase III or IV. Therefore, despite the promising preclinical and clinical data publication, more solid scientific efforts are required to clarify the therapeutic value of mushrooms in oncology. |
format | Online Article Text |
id | pubmed-8876642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88766422022-02-26 Anticancer Activities of Mushrooms: A Neglected Source for Drug Discovery Panda, Sujogya Kumar Sahoo, Gunanidhi Swain, Shasank S. Luyten, Walter Pharmaceuticals (Basel) Review Approximately 270 species of mushrooms have been reported as potentially useful for human health. However, few mushrooms have been studied for bioactive compounds that can be helpful in treating various diseases. Like other natural regimens, the mushroom treatment appears safe, as could be expected from their long culinary and medicinal use. This review aims to provide a critical discussion on clinical trial evidence for mushrooms to treat patients with diverse types of cancer. In addition, the review also highlights the identified bioactive compounds and corresponding mechanisms of action among the explored mushrooms. Furthermore, it also discusses mushrooms with anticancer properties, demonstrated either in vitro and/or in vivo models, which have never been tested in clinical studies. Several mushrooms have been tested in phase I or II clinical trials, mostly for treating breast cancer (18.6%), followed by colorectal (14%) and prostate cancer (11.6%). The majority of clinical studies were carried out with just 3 species: Lentinula edodes (22.2%), Coriolus versicolor, and Ganoderma lucidum (both 13.9%); followed by two other species: Agaricus bisporus and Grifola frondosa (both 11.1%). Most in vitro cell studies use breast cancer cell lines (43.9%), followed by lung (14%) and colorectal cancer cell lines (13.1%), while most in vivo animal studies are performed in mice tumor models (58.7%). Although 32 species of mushrooms at least show some promise for the treatment of cancer, only 11 species have been tested clinically thus far. Moreover, most clinical studies have investigated fewer numbers of patients, and have been limited to phase III or IV. Therefore, despite the promising preclinical and clinical data publication, more solid scientific efforts are required to clarify the therapeutic value of mushrooms in oncology. MDPI 2022-01-31 /pmc/articles/PMC8876642/ /pubmed/35215289 http://dx.doi.org/10.3390/ph15020176 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Panda, Sujogya Kumar Sahoo, Gunanidhi Swain, Shasank S. Luyten, Walter Anticancer Activities of Mushrooms: A Neglected Source for Drug Discovery |
title | Anticancer Activities of Mushrooms: A Neglected Source for Drug Discovery |
title_full | Anticancer Activities of Mushrooms: A Neglected Source for Drug Discovery |
title_fullStr | Anticancer Activities of Mushrooms: A Neglected Source for Drug Discovery |
title_full_unstemmed | Anticancer Activities of Mushrooms: A Neglected Source for Drug Discovery |
title_short | Anticancer Activities of Mushrooms: A Neglected Source for Drug Discovery |
title_sort | anticancer activities of mushrooms: a neglected source for drug discovery |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876642/ https://www.ncbi.nlm.nih.gov/pubmed/35215289 http://dx.doi.org/10.3390/ph15020176 |
work_keys_str_mv | AT pandasujogyakumar anticanceractivitiesofmushroomsaneglectedsourcefordrugdiscovery AT sahoogunanidhi anticanceractivitiesofmushroomsaneglectedsourcefordrugdiscovery AT swainshasanks anticanceractivitiesofmushroomsaneglectedsourcefordrugdiscovery AT luytenwalter anticanceractivitiesofmushroomsaneglectedsourcefordrugdiscovery |